The Congenital Hyperinsulinism International (CHI) Hyperinsulinism Centers of Excellence (COE) Program designates centers for providing the highest quality of care for congenital hyperinsulinism (HI) patients and their families around the world.
In June 2021, the first group of centers received the COE designation. This honor recognizes expert centers that provide the highest level of multi-disciplinary care to congenital hyperinsulinism patients and their families and an on-going commitment to research and collaboration.
The CHI COEs are:
- Congenital Hyperinsulinism Center at the Children’s Hospital of Philadelphia, PA, United States
- The Hyperinsulinism Center at Cook Children’s Medical Center in Fort Worth, TX, United States
- Great Ormond Street Hospital Congenital Hyperinsulinism Service in London, in the United Kingdom
- Charite-Universitatsmedizin Berlin and the University Children’s Hospital Duesseldorf partnership in Germany
- Collaborative Alliance on Congenital Hyperinsulinism headquartered in Magdeburg, Germany
- Northern Congenital Hyperinsulinism Service in Manchester and Liverpool, in the United Kingdom
Read the full press release here.
Press release also available in German here.
History of the COE Program
Every year, around the globe, thousands of babies are born with HI. They need appropriate and expert care to reduce the risk of brain damage and death, and to ensure proper management of their disease for the best possible quality of life, as do all children and adults living with HI.
There are some superb institutions known for providing excellent HI care and participating in groundbreaking research, yet until now there has not been a review process or certificate awarded to institutions for the care of those with HI.
The CHI COE designation application was developed by an international committee of HI specialists, clinicians, and patient representatives who worked together to identify the requirements. The criteria include demonstrated excellence in clinical care, academic research, collaboration, and a commitment to patient care.
Hyperinsulinism centers from all over the world were invited to submit an application to receive the designation. The online application consists of 33 questions that are associated with identified criteria to determine comprehensive and expert HI care. Centers can review the application criteria and scoring by reviewing the COE Application Rubric here.
If you have any questions, please contact Tai Pasquini, CHI Director of Research and Policy, by emailing [email protected] or calling her at 973-842-7559.
The CHI COE Program was made possible through the Global Genes 2020 RARE Patient Impact Grant Program, the Chan Zuckerberg Initiative Rare As One Grant, and other generous donors.
